Use of Direct Oral Anticoagulants in Adult Congenital Heart Disease: A Preliminary Clinical Experience

Objectives: Thromboembolic events (TEE) are common in adults with congenital heart disease (ACHD) and morbidity and mortality from these complications are high. Adequate oral anticoagulation (OAC) for prophylaxis or treatment of TEE is of outstanding importance. Until now, mainly vitamin K antagonists (VKA) have been used in these patients. The purpose of this study was to provide first data on the use of Direct Oral Anticoagulants (DOAC) in ACHD.